Mirabella Financial Services’s BioMarin Pharmaceuticals BMRN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
– Sell
-10,043
Closed -$597K – 935
2025
Q4
$597K Buy
+10,043
New +$547K 0.06% 207
2024
Q3
– Sell
-2,487
Closed -$205K – 197
2024
Q2
$205K Buy
+2,487
New +$207K 0.01% 393
2023
Q2
– Sell
-25,652
Closed -$1.33M – 499
2023
Q1
$1.33M Sell
25,652
-8,232
-24% -$853K 0.2% 94
2022
Q4
$3.51M Buy
33,884
+30,940
+1,051% +$2.9M 0.31% 57
2022
Q3
$250K Sell
2,944
-3,416
-54% -$304K 0.03% 249
2022
Q2
$527K Buy
+6,360
New +$506K 0.05% 238
2021
Q1
– Sell
-5,257
Closed -$461K – 290
2020
Q4
$461K Buy
+5,257
New +$417K 0.06% 177

Other funds holding BMRN

Mirabella Financial Services's BMRN Position: Q1 2026 in Review

Mirabella Financial Services sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2026, closing a stake of 10,043 shares — an estimated $597K sold.

Mirabella Financial Services first reported a position in BMRN in Q4 2020 and held it in 7 quarters. The position peaked at $3.51M in Q4 2022. 559 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.

  • Mirabella Financial Services reported no remaining BioMarin Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Mirabella Financial Services sold 10,043 BioMarin Pharmaceuticals shares in Q1 2026, an estimated $597K.
  • Mirabella Financial Services first reported a position in BioMarin Pharmaceuticals in Q4 2020 and held it in 7 quarters.
  • Mirabella Financial Services's BioMarin Pharmaceuticals position peaked at $3.51M in Q4 2022.
  • 559 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.

Based on Mirabella Financial Services's 13F filing for Q1 2026, filed 12 May 2026.